Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Qiagen NV    QGEN   NL0000240000

QIAGEN NV (QGEN)

Delayed Quote. Delayed  - 06/28 09:59:59 pm
20.73 USD   +2.67%
06/23 QIAGEN NV : Announces Successful Completion of Tender Offer for Shar..
06/21 QIAGEN NV : Joins Consortium to Map Microbial Genomes in 54 Cities
06/21 QIAGEN NV : joins consortium to map microbial genomes in 54 cities
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

QIAGEN NV : Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/03/2010 | 02:05pm CEST

VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN) today announced the Webcast of its second quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.


                    Webcast of QIAGEN's second quarter 2010 financial
    What:            results call

    When:           9:30 a.m. EDT on August 10

                    The Webcast is accessible at www.qiagen.com/goto/
    Where:           ConferenceCall

    How:            Log on to the Web at the address above

                    The corresponding presentation slides will be
                    available for download in the investor relations
                    section of QIAGEN's Web site at www.qiagen.com/
                    goto/ConferenceCall.

                    Andreas Marathovouniotis, Russo Partners, (212)
    Contact:        845-4235

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, or The Windows Media Player, downloadable free from www.microsoft.com and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to prnwebcast@multivu.com.)

SOURCE QIAGEN N.V.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on QIAGEN NV
06/23 QIAGEN NV : Announces Successful Completion of Tender Offer for Shares in Exiqon
06/21 QIAGEN NV : Joins Consortium to Map Microbial Genomes in 54 Cities
06/21 QIAGEN NV : joins consortium to map microbial genomes in 54 cities
06/14 QIAGEN NV : Launches QIAsure Methylation Test to Determine Cervical Cancer Risk
06/14 QIAGEN NV : Names for the dead, certainty for the survivors
06/14 QIAGEN NV : Finding lost loved-ones – and inner peace
06/08 QIAGEN NV : Changes Offer Conditions for Acquisition of Shares in Exiqon A/S
06/08 QIAGEN NV : changes offer conditions for acquisition of shares in Exiqon A/S
06/03 QIAGEN NV : Announces Second Offer Extension for the Acquisition of Shares in Ex..
06/02 QIAGEN NV : Forms Lung Cancer Expert Alliance